Publications by authors named "S Shinomiya"

This paper explores how what I call 'administrative categories' have been adopted by the Japanese government and experts in autism support and what roles these categories have played in local settings. Since support practices for children and adults with autism began in the 1950s in Japan, the Japanese government and people engaging in autism support have used Japanese-specific administrative categories, instead of relying on a medical concept of autism, such as 'severe moving disabilities' (SMD), 'emotional disturbance', and 'extremely disruptive behavioural disorders' (EDBD). To understand the emergence of these three autism-related administrative categories in Japan, historical materials published from the 1950s to the 1990s by Japanese authors (doctors, psychologists, teachers, educationalists, welfare workers, government officials, and parents) and interview data with 19 leading experts of autism in Japan were collected and analysed thematically.

View Article and Find Full Text PDF

Background: Pemetrexed (PEM) is the primary chemotherapy for non-small cell lung cancer (NSCLC), showing potential for long-term disease stability in certain cases. However, studies examining disease control with PEM therapy are lacking. This study aimed to pinpoint clinical traits in patients with NSCLC responding well to PEM therapy, predict factors influencing disease control, and suggest optimal treatment approaches.

View Article and Find Full Text PDF

Background: Sarcopenia, characterized by skeletal muscle atrophy and physical inactivity, is a manifestation of chronic obstructive pulmonary disease (COPD) and is associated with a poor prognosis. The serum creatinine (Cr)/cystatin C (CysC) ratio has been proposed as a marker of sarcopenia, given its correlation with total skeletal muscle mass, and as a prognostic indicator in COPD. This study aimed to evaluate the usefulness of the serum Cr/CysC ratio as a prognostic determinant in these patients.

View Article and Find Full Text PDF

Revised idiopathic pulmonary fibrosis treatment guidelines were published in 2015, and nintedanib was conditionally recommended. Although diarrhea is reported to be a common major adverse event associated with nintedanib, there have been few reports on detailed endoscopic findings of nintedanib-associated enterocolitis. A 74-year-old woman was diagnosed with idiopathic pulmonary fibrosis 4 years ago in May.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of docetaxel (DTX) and DTX plus ramucirumab (RAM) as second-line treatments for advanced non-small cell lung cancer (NSCLC), aiming to identify which patients are more likely to respond to these therapies.
  • Out of 53 analyzed patients, only 22.6% showed a positive response to the treatments, with significant factors predicting nonresponse being lack of prior immune checkpoint inhibitors and reduction in DTX dosage after the second cycle.
  • The findings indicate that maintaining DTX dosage and avoiding treatment with immune checkpoint inhibitors before administering DTX or DTX + RAM could improve response rates and overall survival in NSCLC patients.
View Article and Find Full Text PDF